This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CyIS, Aerosolized Cyclosporine
Description: PULMINIQ is an inhaled formulation of cyclosporine, an FDA-approved drug that has been part of the standard of care for heart, kidney and liver transplant patients for more than 20 years. Cyclosporine is a powerful immunosuppressant that has had a significant impact on transplant medicine. It inactivates T cells by inhibiting calcineurin phosphatase activity resulting in the inhibition of the transcription factor nuclear factor of activated T cells (NFAT).
Pink Sheet Pulminiq delay
Additional information available to subscribers only: